Holen Sie sich die Stockscreener-App
55.26
4.49%
-2.6361
Schlusskurs vom Vortag:
$57.90
Offen:
$58.09
24-Stunden-Volumen:
2.01M
Relative Volume:
1.65
Marktkapitalisierung:
$4.60B
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-345.91M
KGV:
-12.67
EPS:
-4.3602
Netto-Cashflow:
$-280.51M
1W Leistung:
+31.86%
1M Leistung:
+33.32%
6M Leistung:
+52.72%
1J Leistung:
+57.19%
1-Tages-Spanne:
$54.93
$59.00
1-Wochen-Bereich:
$54.93
$63.95
52-Wochen-Spanne:
$26.74
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
55.25 | 4.82B | 7.50M | -345.91M | -280.51M | -4.3602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.36 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.68 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.39 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.56 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.18 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals closes $747.5M public offering - Investing.com South Africa
Xenon Pharmaceuticals closes US $747.5M public offering - Private Capital Journal
Xenon Pharmaceuticals Closes $747.5 Million Public Offering - marketscreener.com
BofA raises Xenon Pharmaceuticals price target on trial success - Investing.com
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants - TradingView
Xenon Pharmaceuticals closes $747.5M public offering By Investing.com - Investing.com UK
Xenon Pharmaceuticals Announces Closing of $747.5 Million - GlobeNewswire
Xenon Pharmaceuticals launches $500 million stock offering By Investing.com - Investing.com Nigeria
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE) - The Chronicle-Journal
Is Xenon Pharmaceuticals (XENE) Pricing Look Compelling After Recent 37% Weekly Share Surge? - simplywall.st
What is HC Wainwright's Estimate for XENE FY2027 Earnings? - MarketBeat
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results - MSN
Ian Mortimer Sells 11,269 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 270,000 Shares - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells 2,771 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $156,706.77 in Stock - MarketBeat
XENE Expands Stock Offering to $650 Million - GuruFocus
Xenon Pharmaceuticals prices $650M public offering at $57/share - Investing.com Australia
Xenon Pharmaceuticals prices $650M public offering at $57/share By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Xenon Pharmaceuticals Prices Upsized $650 Million Public Offering of Shares - marketscreener.com
Liquidity Mapping Around (XENE) Price Events - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Upsizes Public Offering to $650 Mil - GuruFocus
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewswire
Xenon Raises $650 Million in Upsized U.S. Equity Offering - TipRanks
Xenon Pharmaceuticals announces pricing of upsized $650.0 million public offering - marketscreener.com
Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million - Quiver Quantitative
Biotech Xenon raises $650M in stock sale at $57 a share - Stock Titan
Xenon Pharmaceuticals Announces Pricing Of Upsized $650.0 Million Public Offering - TradingView
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewswire Inc.
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study - Bitget
Why Xenon Pharmaceuticals (XENE) Is Up 38.4% After Strong Phase 3 Azetukalner Seizure Data And FDA Plans - simplywall.st
Xenon Pharmaceuticals announces proposed $500M public share offering - MSN
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy - TipRanks
XENE: Wells Fargo Raises Price Target by 38.78% on Overweight Ra - GuruFocus
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE) - FinancialContent
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
XENE: Wedbush Raises Price Target for Xenon Pharmaceuticals | XE - GuruFocus
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $64.00 at Wedbush - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - MarketBeat
XENE: HC Wainwright Raises Price Target for Xenon Pharmaceuticals | XENE Stock News - GuruFocus
Xenon Pharmaceuticals stock reaches all-time high at 60.5 USD By Investing.com - Investing.com Canada
XENE Announces Positive Phase 3 Results for Epilepsy Treatment - GuruFocus
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ - Stocktwits
Xenon’s Seizure Drug Data Make A Strong Case For Clinical Use - Citeline News & Insights
Xenon Pharmaceuticals’ Strategic Moves Signal New Opportunities in Epilepsy Screening - timothysykes.com
Xenon Pharmaceuticals Announces Proposed Public Offering - TradingView
Xenon Pharmaceuticals (XENE) Launches $500M Public Offering - GuruFocus
Why This Biotech, Up 47%, Could Spark The Next Buyout Frenzy - Investor's Business Daily
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DiFabio Andrea | Chief Legal Officer |
Mar 10 '26 |
Sale |
60.11 |
2,607 |
156,702 |
4,893 |
| MORTIMER IAN | PRESIDENT & CEO |
Mar 09 '26 |
Option Exercise |
6.74 |
270,000 |
1,819,850 |
111,000 |
| MORTIMER IAN | PRESIDENT & CEO |
Mar 09 '26 |
Sale |
60.33 |
270,000 |
16,289,142 |
6,000 |
| MORTIMER IAN | PRESIDENT & CEO |
Mar 10 '26 |
Sale |
60.11 |
11,269 |
677,357 |
14,731 |
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):